OXA-48-producing Enterobacteriaceae were associated with community-onset, healthcare acquisition.
Metallo-β-lactamase (MBL) producers occurred more frequently in ICU patients.
OXA-48-producers caused urinary tract infection more frequently than MBL producers.
Only 10% of infections were bacteraemic.
Non-active targeted therapy was independently associated with increased mortality.